BACKGROUND AND OBJECTIVES: Sarcopenia is common in hemodialysis patients. This study examined whether the anabolic steroid oxymetholone improves muscle mass and handgrip strength in hemodialysis patients and possible mechanisms that might engender such changes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Forty-three eligible hemodialysis patients were randomly assigned to ingest oxymetholone or placebo for 24 weeks. Body composition, handgrip strength, and quality of life were measured during the study. Muscle biopsies were performed and analyzed for mRNA levels for myostatin, IGF-I, IGF binding proteins, and myosin heavy chains and protein expression. Muscle fiber types and diameter were assessed by reduced nicotinamide-adenine dinucleotide staining. RESULTS: There was a significantly greater increase in fat-free mass and handgrip strength and decrease in fat mass in the oxymetholone compared with the placebo group. Moreover, compared with baseline values, patients given oxymetholone exhibited an increase in fat-free mass, handgrip strength, physical functioning scores, and type I muscle fiber cross-sectional area and a decrease in fat mass, whereas patients receiving placebo did not undergo changes. There was a significantly greater increase in muscle mRNA levels for myosin heavy chain 2×, IGF-I, and IGF-II receptor with oxymetholone treatment than placebo. Liver enzyme rose significantly in the oxymetholone group, but the number of values greater than three times the upper limit of normal were not different between these groups. CONCLUSIONS: In hemodialysis patients, ingesting oxymetholone was associated with an increase in fat-free mass, handgrip strength, and muscle mRNA levels for several growth factors and a decrease in fat mass, but it also induced liver injury.
RCT Entities:
BACKGROUND AND OBJECTIVES:Sarcopenia is common in hemodialysis patients. This study examined whether the anabolic steroidoxymetholone improves muscle mass and handgrip strength in hemodialysis patients and possible mechanisms that might engender such changes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Forty-three eligible hemodialysis patients were randomly assigned to ingest oxymetholone or placebo for 24 weeks. Body composition, handgrip strength, and quality of life were measured during the study. Muscle biopsies were performed and analyzed for mRNA levels for myostatin, IGF-I, IGF binding proteins, and myosin heavy chains and protein expression. Muscle fiber types and diameter were assessed by reduced nicotinamide-adenine dinucleotide staining. RESULTS: There was a significantly greater increase in fat-free mass and handgrip strength and decrease in fat mass in the oxymetholone compared with the placebo group. Moreover, compared with baseline values, patients given oxymetholone exhibited an increase in fat-free mass, handgrip strength, physical functioning scores, and type I muscle fiber cross-sectional area and a decrease in fat mass, whereas patients receiving placebo did not undergo changes. There was a significantly greater increase in muscle mRNA levels for myosin heavy chain 2×, IGF-I, and IGF-II receptor with oxymetholone treatment than placebo. Liver enzyme rose significantly in the oxymetholone group, but the number of values greater than three times the upper limit of normal were not different between these groups. CONCLUSIONS: In hemodialysis patients, ingesting oxymetholone was associated with an increase in fat-free mass, handgrip strength, and muscle mRNA levels for several growth factors and a decrease in fat mass, but it also induced liver injury.
Authors: A Rashid Qureshi; Anders Alvestrand; José C Divino-Filho; Alberto Gutierrez; Olof Heimbürger; Bengt Lindholm; Jonas Bergström Journal: J Am Soc Nephrol Date: 2002-01 Impact factor: 10.121
Authors: Arny A Ferrando; Melinda Sheffield-Moore; Catherine W Yeckel; Charles Gilkison; Jie Jiang; Alison Achacosa; Steven A Lieberman; Kevin Tipton; Robert R Wolfe; Randall J Urban Journal: Am J Physiol Endocrinol Metab Date: 2002-03 Impact factor: 4.310
Authors: Indrani Sinha-Hikim; Jorge Artaza; Linda Woodhouse; Nestor Gonzalez-Cadavid; Atam B Singh; Martin I Lee; Thomas W Storer; Richard Casaburi; Ruoquing Shen; Shalender Bhasin Journal: Am J Physiol Endocrinol Metab Date: 2002-07 Impact factor: 4.310
Authors: Garland A Campbell; James T Patrie; Bruce D Gaylinn; Michael O Thorner; Warren K Bolton Journal: Nephrol Dial Transplant Date: 2018-03-01 Impact factor: 5.992
Authors: Naohito Isoyama; Abdul Rashid Qureshi; Carla Maria Avesani; Bengt Lindholm; Peter Bàràny; Olof Heimbürger; Tommy Cederholm; Peter Stenvinkel; Juan Jesús Carrero Journal: Clin J Am Soc Nephrol Date: 2014-07-29 Impact factor: 8.237
Authors: Paulo Gentil; Claudio Andre Barbosa de Lira; Antonio Paoli; José Alexandre Barbosa Dos Santos; Roberto Deivide Teixeira da Silva; José Romulo Pereira Junior; Edson Pereira da Silva; Rodrigo Ferro Magosso Journal: Eur J Transl Myol Date: 2017-03-24